Literature DB >> 21418443

The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity.

S Revel-Vilk1, P Komvilaisak, V Blanchette, A M Stain, G Floros, A Cochrane, C Blanchette, M Hang, E A Roberts, S C Ling.   

Abstract

Hepatitis in children with haemophilia was historically most often associated with transfusion-transmitted infections. However, with the use of recombinant clotting factor concentrates, acquisition of such infections has now become rare. We studied the profile of hepatitis in North-American children with haemophilia in the modern era of safe blood products and excess childhood obesity. A total of 173 boys (<18 years) registered in the Pediatric Comprehensive Care Haemophilia Program were included in this retrospective study. Hospital records were reviewed for baseline data, serial height and weight measurements and serial alanine aminotransferase (ALT) levels. A body mass index (BMI) ranking was available for 170 boys, of whom 25 (14.7%, 95% CI 9.7-20.9%) were obese. The rate of obesity was higher in severe haemophilic boys. Compared with the general childhood population, the rate of obesity trended towards being higher in young haemophilic boys (2-5 years), but was similar in other age groups. A persistently high ALT (≥80 U L(-1) ) was documented in 5 boys and was associated with obesity. Three boys had clinical and imaging studies compatible with non-alcoholic fatty liver disease (NAFLD). Overweight and obesity are common among haemophilic boys, especially those who are younger and with severe disease. In this large group of haemophilic boys, chronic viral hepatitis was rare and NAFLD was a more common cause of liver disease. Overweight and obese haemophilic boys should be evaluated for NAFLD and interventional programmes should be designed to reduce the potential complications associated with obesity.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21418443     DOI: 10.1111/j.1365-2516.2010.02477.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model.

Authors:  Alaknanda Mishra; Shailendra Arindkar; Preeti Sahay; Jerald Mahesh Kumar; Pramod K Upadhyay; Subeer S Majumdar; Perumal Nagarajan
Journal:  Int J Exp Pathol       Date:  2018-04-15       Impact factor: 1.925

2.  The role of disease severity in influencing body mass index in people with haemophilia: a single-institutional cross-sectional study.

Authors:  M McNamara; A Antun; C L Kempton
Journal:  Haemophilia       Date:  2013-10-14       Impact factor: 4.287

3.  An inventory of healthy weight practices in federally funded haemophilia treatment centres in the United States.

Authors:  E Adams; J Deutsche; E Okoroh; S Owens-McAlister; S Majumdar; M Ullman; M L Damiano; M Recht
Journal:  Haemophilia       Date:  2014-03-16       Impact factor: 4.287

4.  Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.

Authors:  Alanna McEneny-King; Pierre Chelle; Severine Henrard; Cedric Hermans; Alfonso Iorio; Andrea N Edginton
Journal:  Pharmaceutics       Date:  2017-10-17       Impact factor: 6.321

5.  Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.

Authors:  Steven W Pipe; Rebecca Kruse-Jarres; Johnny N Mahlangu; Glenn F Pierce; Flora Peyvandi; Peter Kuebler; Christian De Ford; Fabián Sanabria; Richard H Ko; Tiffany Chang; Charles R M Hay
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

6.  Prevalence of non-Alcoholic Fatty Liver Disease and Associated Factors in Patients with Moderate or Severe Hemophilia: A Multicenter-Based Study.

Authors:  Ming-Ching Shen; Shyh-Shin Chiou; Sheng-Chieh Chou; Te-Fu Weng; Ching-Yeh Lin; Jiaan-Der Wang; Shou-Wu Lee; Ching-Tien Peng
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.